glp-1 drugs moa Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Graphical presentation of the mechanism

It does not compete directly on maximum weight loss with injectable multi-receptor agonists but instead offers a differentiated value proposition based on oral convenience, no restrictions, lower manufacturing costs, and the potential to dramatically expand the addressable patient population for GLP-1 therapy

Gallwitz, B

The main difference, really, is that folks with atypical anorexia are within the normal or above weight range, according to BMI, while someone with anorexia nervosa would have BMI in the underweight range, says Sara Bartel, a psychologist specializing in eating disorders at Nova Scotia Health in Canada

The early clinical adoption suggests that some practitioners believe the potential benefits outweigh the risks

Then theres also the question of efficacy

Expect 50-70% cheaper options vs